ESR1 and breast cancer: In premenopausal low-risk ER+ breast cancer, the preferred therapeutic approach includes selective estrogen receptor modulators like tamoxifen, which have a greater affinity for breast ER than E2, and thus are able to displace them and bind themselves to the ER [1,4].